TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11709366

Group type: EXPERIMENTAL
Intervention: Amprenavir with saquinavir soft gel capsule
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amprenavir with indinavir
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Amprenavir with nelfinavir
Number of subjects: 31

Group type: COMPARATOR
Intervention: Nelfinavir and saquinavir with amprenavir
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Indinavir with amprenavir
Number of subjects: 31
Study: 9046304

Group type: EXPERIMENTAL
Intervention: 2 mg/kg per day tirilazad
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: 6 mg/kg per day tirilazad
Number of subjects: 897

Group type: COMPARATOR
Intervention: Placebo (vehicle)
Number of subjects: 897

Group type: EXPERIMENTAL
Intervention: All groups (including placebo and both doses of tirilazad)
Number of subjects: 897
Study: 7931028

Group type: EXPERIMENTAL
Intervention: 15‐mg diphenhydramine hydrochloride (Benadryl) local injection
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sterile saline (control group)
Number of subjects: 37
Study: 3336177

Group type: EXPERIMENTAL
Intervention: Interferon alfa (Alferon N Injection), injected into lesions twice weekly for up to eight weeks.
Number of subjects: 158

Group type: COMPARATOR
Intervention: Placebo, injected into lesions twice weekly for up to eight weeks.
Number of subjects: 158
Study: 30342242

Group type: EXPERIMENTAL
Intervention: Dementia-specific specialty palliative care consultation plus postacute transitional care
Number of subjects: 62

Group type: COMPARATOR
Intervention: Usual care and educational information
Number of subjects: 62
Study: 28302543

Group type: EXPERIMENTAL
Intervention: Pidotimod (PDT) 800mg, 2 daily doses
Number of subjects: 16

Group type: COMPARATOR
Intervention: Levofloxacin 500 mg b.i.d. alone
Number of subjects: 16
Study: 26894598

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 120
Study: 23343392

Group type: EXPERIMENTAL
Intervention: Coordinated pharmacological bone health and falls prevention program post-fracture
Number of subjects: 1596

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 1596
Study: 21701222

Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate at a dose of 50 mg/kg/day for 10 days
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Oral erythromycin ethylsuccinate
Number of subjects: 60
Study: 19051397

Group type: EXPERIMENTAL
Intervention: Oral tenofovir HIV prevention trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: HIV prevention counseling associated with the trial
Number of subjects: 0
Study: 15080578

Group type: EXPERIMENTAL
Intervention: Clonidine (0.1 mg every 12 hours for 7 days)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Enalapril (5 mg every 12 hours for 7 days)
Number of subjects: 81

Group type: COMPARATOR
Intervention: Control (no treatment)
Number of subjects: 81
Study: 12243437

Group type: EXPERIMENTAL
Intervention: Carmeda Bio‐Active Surface (CBAS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Duraflo II coating
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (CBAS and Duraflo II)
Number of subjects: 40
Study: 9824784

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 2 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 3.5 hours
Number of subjects: 26

Group type: COMPARATOR
Intervention: Cisplatin (CDDP) 80 mg/m2 by infusion over 4 hours
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) pharmacodynamics
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) pharmacokinetics
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) nephrotoxicity management
Number of subjects: 26
Study: 8109552

Group type: EXPERIMENTAL
Intervention: L-thyroxine (100 micrograms/day)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2697690

Group type: EXPERIMENTAL
Intervention: Glycine fortified oral rehydration solution (ORS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard ORS (WHO formula)
Number of subjects: 0
Study: 1256990

Group type: EXPERIMENTAL
Intervention: Work intensity at 60% of HRmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work intensity at 75% of HRmax
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Work intensity at 90% of HRmax
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 31286425

Group type: EXPERIMENTAL
Intervention: PHIV+
Number of subjects: 39
Study: 27510440

Group type: EXPERIMENTAL
Intervention: Irremovable instant total contact cast (iTCC)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Removable cast walker (RCW)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: RCW patients
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Standing duration
Number of subjects: 49
Study: 25813474

Group type: EXPERIMENTAL
Intervention: Psycho-educational oncology interventions
Number of subjects: 0
Study: 23140612

Group type: EXPERIMENTAL
Intervention: Hydrocortisone (17 mg/kg cumulative dose)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 21569094

Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse (0.2% CHX)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo mouthrinse
Number of subjects: 50
Study: 19633166

Group type: EXPERIMENTAL
Intervention: eAG
Number of subjects: 80

Group type: COMPARATOR
Intervention: A1C
Number of subjects: 80
Study: 16394754

Group type: EXPERIMENTAL
Intervention: Dynamic extensor brace treatment for 12 weeks (Group 1; n = 30)
Number of subjects: 63

Group type: COMPARATOR
Intervention: No brace treatment (Group 2; n = 33)
Number of subjects: 63
Study: 15175795

Group type: EXPERIMENTAL
Intervention: Diet intervention (Mediterranean type diet)
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: VLC n‐3 supplementation
Number of subjects: 219

Group type: EXPERIMENTAL
Intervention: Dietary advice (Mediterranean type diet)
Number of subjects: 219

Group type: COMPARATOR
Intervention: Placebo (corn oil)
Number of subjects: 219
Study: 11521726

Group type: EXPERIMENTAL
Intervention: AC → paclitaxel + trastuzumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: AC → paclitaxel
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AC → paclitaxel + tamoxifen
Number of subjects: 0
Study: 9230637

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NTP) 70 mg initially, increased to 75 mg based on serum levels
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Nortriptyline (NTP) treatment
Number of subjects: 16
Study: 8231841

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) for 6 weeks
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) for 26 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo treatment for 6 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo treatment for 26 weeks
Number of subjects: 9
Study: 3631260

Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at 0.1 microgram/min
Number of subjects: 5

Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 5
Study: 30882163

Group type: EXPERIMENTAL
Intervention: Irrigation fluid at 37°C (GroupW)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Irrigation fluid at room temperature (GroupRT)
Number of subjects: 60
Study: 28926170

Group type: EXPERIMENTAL
Intervention: Saxagliptin 5 mg plus metformin
Number of subjects: 630

Group type: COMPARATOR
Intervention: Saxagliptin 5 mg plus placebo
Number of subjects: 630

Group type: COMPARATOR
Intervention: Metformin plus placebo
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Saxagliptin plus metformin
Number of subjects: 630
Study: 27717405

Group type: EXPERIMENTAL
Intervention: Group Cognitive Behavioral Therapy (GCBT)
Number of subjects: 128

Group type: COMPARATOR
Intervention: Group Schema Therapy (GST)
Number of subjects: 128
Study: 24894696

Group type: EXPERIMENTAL
Intervention: ASIR 40 protocol (Group A)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Standard FBP protocol (Group B)
Number of subjects: 53
Study: 22232134

Group type: EXPERIMENTAL
Intervention: Valsartan
Number of subjects: 1150

Group type: COMPARATOR
Intervention: Amlodipine
Number of subjects: 1150

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 1150
Study: 19707760

Group type: EXPERIMENTAL
Intervention: Open wedge osteotomy (OWO)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Closed wedge osteotomy (CWO)
Number of subjects: 50
Study: 18247099

Group type: EXPERIMENTAL
Intervention: Endotherapy (trans‐ampullary pancreatic stents for drainage)
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Surgical resections
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Surgical drainage
Number of subjects: 380

Group type: EXPERIMENTAL
Intervention: Endotherapy with or without shock wave lithotripsy
Number of subjects: 380
Study: 28406090

Group type: EXPERIMENTAL
Intervention: 2 evogliptin/metformin XR 2.5/500 mg FDC tablets
Number of subjects: 33

Group type: COMPARATOR
Intervention: Separate formulations of evogliptin 5 mg and metformin XR 1,000 mg
Number of subjects: 33
Study: 11855559

Group type: EXPERIMENTAL
Intervention: Corticosteroid withdrawal therapy (CSWT) alone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Corticosteroid withdrawal therapy (CSWT) followed by interferon-alpha (IFN-alpha)
Number of subjects: 42
Study: 10378970

Group type: EXPERIMENTAL
Intervention: Comprehensive radiotherapy after aggressive surgery and chemotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Regional irradiation incorporating internal mammary nodes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Optimal sequencing of radiotherapy and chemotherapy
Number of subjects: 0
Study: 7794631

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 5
Study: 2260546

Group type: EXPERIMENTAL
Intervention: Mortality survey for cardiovascular disease
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Morbidity survey for myocardial infarction and stroke
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Clinical examination
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Personal interviews
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Physical examination
Number of subjects: 4500

Group type: EXPERIMENTAL
Intervention: Laboratory measurements
Number of subjects: 4500
Study: 15295

Group type: EXPERIMENTAL
Intervention: Medazepam (16.5 mg daily)
Number of subjects: 14
Study: 31232684

Group type: EXPERIMENTAL
Intervention: Nocturnal temperature-controlled laminar airflow (TLA) device
Number of subjects: 240

Group type: COMPARATOR
Intervention: Placebo device
Number of subjects: 240
Study: 28711811

Group type: EXPERIMENTAL
Intervention: n-acetylcysteine (2400 mg/day)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 25583758

Group type: EXPERIMENTAL
Intervention: DCR+RCR group (Distal Clavicle Resection + Rotator Cuff Repair)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Isolated RCR group (Rotator Cuff Repair only)
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: DCR+RCR group
Number of subjects: 56

Group type: COMPARATOR
Intervention: Isolated RCR group
Number of subjects: 56
Study: 23815302

Group type: EXPERIMENTAL
Intervention: 2-dose alemtuzumab (15 mg at day 0 and 15 mg repeated on day 7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daclizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional 4-dose alemtuzumab
Number of subjects: 0
Study: 21658528

Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Community care condition
Number of subjects: 49
Study: 19548434

Group type: EXPERIMENTAL
Intervention: Jiawei Xiaoyao Powder (JXYP)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Estazolam (WM group)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: JXYP plus Estazolam (IM group)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo (Control group)
Number of subjects: 33
Study: 16940830

Group type: EXPERIMENTAL
Intervention: Once-daily amoxicillin (750 mg or 1000 mg) for 10 days
Number of subjects: 652

Group type: COMPARATOR
Intervention: Twice-daily amoxicillin (2 doses of 375 mg or 500 mg) for 10 days
Number of subjects: 652

Group type: EXPERIMENTAL
Intervention: Once-daily amoxicillin
Number of subjects: 652

Group type: COMPARATOR
Intervention: Twice-daily amoxicillin
Number of subjects: 652
Study: 15473127

Group type: EXPERIMENTAL
Intervention: Single dose sulfonylurea (Glimepiride 8 patients, gliclazide 5 patients)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Repaglinide 2 x 2 mg
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Diabetic diet only
Number of subjects: 52

Group type: COMPARATOR
Intervention: Single dose sulfonylurea (Group 2)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Repaglinide (Group 3)
Number of subjects: 52
Study: 11157881

Group type: EXPERIMENTAL
Intervention: Manifest refraction
Number of subjects: 29

Group type: COMPARATOR
Intervention: Autorefraction
Number of subjects: 29
Study: 11015795

Group type: EXPERIMENTAL
Intervention: Trivalent inactivated influenza vaccine (n = 595 in 1997-1998; n = 587 in 1998-1999)
Number of subjects: 2375

Group type: COMPARATOR
Intervention: Sterile saline injection (placebo; n = 589 in 1997-1998; n = 604 in 1998-1999)
Number of subjects: 2375
Study: 8783304

Group type: EXPERIMENTAL
Intervention: Local anesthetic cream
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control cream
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Isometric contraction at 22% MVC
Number of subjects: 28
Study: 1617901

Group type: EXPERIMENTAL
Intervention: True mud packs (Group 1)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Washed out and less concentrated mud packs (Group 2)
Number of subjects: 28
Study: 6547072

Group type: EXPERIMENTAL
Intervention: Combination chemotherapy (Adriamycin 25 mg/m2, cyclophosphamide 700 mg/m2, vincristine 1.5 mg/m2, arabinosylcytosine 100 mg/m2, methotrexate 10 mg/m2, prednisone 60 mg/m2) and radiotherapy (2000 rad)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Combination chemotherapy and radiotherapy
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Pseudomonas vaccine
Number of subjects: 73
Study: 29982844

Group type: EXPERIMENTAL
Intervention: Full range of motion (FULL) training
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Partial range of motion (PART) training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (Control)
Number of subjects: 19
Study: 26791569

Group type: EXPERIMENTAL
Intervention: Computerised interpretation of the CTG with decision-support
Number of subjects: 46000

Group type: COMPARATOR
Intervention: Control group (standard care without decision-support)
Number of subjects: 46000
Study: 23124275

Group type: EXPERIMENTAL
Intervention: Therapist self-report measure of evidence-based practices (ITT-ABP)
Number of subjects: 71
Study: 22342006

Group type: EXPERIMENTAL
Intervention: Corneal collagen crosslinking (CXL)
Number of subjects: 76
Study: 20332354

Group type: EXPERIMENTAL
Intervention: Continuous Glucose Monitoring (CGM)
Number of subjects: 2
Study: 17679725

Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 8650

Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 8650

Group type: EXPERIMENTAL
Intervention: Centrally assessed ER and PgR
Number of subjects: 8650

Group type: EXPERIMENTAL
Intervention: Centrally assessed hormone receptor status
Number of subjects: 8650
Study: 15910745

Group type: EXPERIMENTAL
Intervention: Detection of novel truncated isoforms of SAA4 using MALDI-TOF MS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patterns of isoform distribution
Number of subjects: 0
Study: 11903513

Group type: EXPERIMENTAL
Intervention: Piribedil (3 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9874055

Group type: EXPERIMENTAL
Intervention: Withdrawal of antihypertensive medication
Number of subjects: 975

Group type: COMPARATOR
Intervention: Nonpharmacologic therapy (weight loss and/or sodium reduction)
Number of subjects: 975
Study: 9139386

Group type: EXPERIMENTAL
Intervention: Albendazole (400 mg twice daily for 5 days)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Thiabendazole (1 g twice daily for 5 days)
Number of subjects: 35
Study: 2229463

Group type: COMPARATOR
Intervention: Flurazepam 30 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Flurazepam 15 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Midazolam 15 mg
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 99
Study: 31621538

Group type: EXPERIMENTAL
Intervention: Friend PSA
Number of subjects: 188

Group type: EXPERIMENTAL
Intervention: Labeling PSA
Number of subjects: 188
Study: 29723341

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication counseling session at discharge and telephone follow-up three and 15 days after discharge.
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group (no pharmacist-led counseling).
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Pharmacist-led medication counseling session at discharge.
Number of subjects: 104
Study: 26548341

Group type: EXPERIMENTAL
Intervention: Home walking exercise (8 weeks of aerobic conditioning: 60 minutes/day, 5 days/week; followed by 16 weeks of aerobic maintenance: 150 minutes/week, 30 minutes/session at 60-80% of heart rate reserve)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Home walking exercise
Number of subjects: 84
Study: 24563084

Group type: EXPERIMENTAL
Intervention: LIS (nutraceutical product containing Garcinia cambogia, l-carnitine, and Ascophyllum nodosum)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 28
Study: 22196835

Group type: EXPERIMENTAL
Intervention: theory‐based education plus MEMS feedback
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: theory‐based education only
Number of subjects: 82

Group type: COMPARATOR
Intervention: usual care (control)
Number of subjects: 82
Study: 20662896

Group type: EXPERIMENTAL
Intervention: Eslicarbazepine acetate (ESL) 800 mg once daily
Number of subjects: 314
Study: 17717534

Group type: EXPERIMENTAL
Intervention: Sucromalt (50 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HFCS (50 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Sucromalt (80 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: HFCS (80 g)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Fructose/glucose blend (56 g) + inulin (24 g)
Number of subjects: 40
Study: 15765446

Group type: EXPERIMENTAL
Intervention: Capsule endoscopy
Number of subjects: 30
Study: 12441039

Group type: EXPERIMENTAL
Intervention: Various therapies for inflammatory bowel disease (IBD)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical activity indices
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New activity indices
Number of subjects: 0
Study: 10483964

Group type: EXPERIMENTAL
Intervention: Oral verapamil (240 mg/day) initiated three days before cardioversion and continued during follow-up (group II)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Oral verapamil (240 mg/day) administered three days before and continued only for three days after cardioversion (group III)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Oral propafenone (900 mg/day) only (group I)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison of AF free survival curves between group I (propafenone only) and group II (verapamil + propafenone)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Comparison of AF free survival curves between group I (propafenone only) and group III (verapamil before and after cardioversion)
Number of subjects: 107
Study: 8758387

Group type: EXPERIMENTAL
Intervention: Mitomycin C (MMC) 0.4 mg/ml used in trabeculectomy
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no MMC)
Number of subjects: 30
Study: 1877445

Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (positive)
Number of subjects: 838

Group type: EXPERIMENTAL
Intervention: Treadmill exercise test (negative)
Number of subjects: 838

Group type: COMPARATOR
Intervention: Positive or negative test result (with or without angina)
Number of subjects: 838
Study: 7045755

Group type: EXPERIMENTAL
Intervention: Penicillin plus gentamicin
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefamandole (2, 1, and 1 g)
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: Cefamandole (2, 2, and 2 g)
Number of subjects: 305
Study: 30328241

Group type: EXPERIMENTAL
Intervention: Mindfulness-based program (MBP) for 8 weeks
Number of subjects: 99

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 99
Study: 28537437

Group type: EXPERIMENTAL
Intervention: In-home closed-loop technology for four nights
Number of subjects: 16
Study: 26427106

Group type: EXPERIMENTAL
Intervention: Zhenjingdingzhi decoction
Number of subjects: 100

Group type: COMPARATOR
Intervention: Suanzaoren decoction
Number of subjects: 100
Study: 24248424

Group type: EXPERIMENTAL
Intervention: Heart rate characteristics monitoring
Number of subjects: 1489
Study: 23503089

Group type: COMPARATOR
Intervention: WB-GTH-Basic intervention
Number of subjects: 247

Group type: COMPARATOR
Intervention: WB-GTH-Enhanced intervention
Number of subjects: 247
Study: 19746201

Group type: EXPERIMENTAL
Intervention: Intradetrusor injections of botulinum toxin‐A (BTX‐A)
Number of subjects: 100
Study: 17309380

Group type: EXPERIMENTAL
Intervention: Tapas Acupressure Technique (TAT)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Self-directed support (SDS)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Qigong (QI)
Number of subjects: 88
Study: 15140336

Group type: EXPERIMENTAL
Intervention: Alendronate 70 mg once weekly
Number of subjects: 449

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study: 11124714

Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibutilide and Dofetilide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Electrical cardioversion
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Procainamide
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lidocaine and Bretylium
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adrenergic blockade
Number of subjects: 0